Nanobiotix ( (NBTX) ) just unveiled an update.
On March 17, 2025, Nanobiotix announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, to strengthen its financial position. The amendment relieves Nanobiotix of funding obligations for the NANORAY-312 trial, with Johnson & Johnson assuming nearly all remaining costs. This adjustment reduces the overall deal value from $2.7 billion to $2.6 billion but maintains significant potential milestone payments. The agreement extends Nanobiotix’s cash visibility to mid-2026 and reduces operational cash burn, positioning the company for long-term stability and profitability.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company focused on pioneering disruptive, physics-based therapeutic approaches to improve treatment outcomes for patients. Founded in 2003 and headquartered in Paris, France, the company is listed on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix specializes in oncology, bioavailability, and biodistribution, and disorders of the central nervous system, owning more than 25 umbrella patents across three nanotechnology platforms.
YTD Price Performance: 11.90%
Average Trading Volume: 20,972
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $151.2M
Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.